恒瑞医药(600276.SH):HRS-9821吸入粉雾剂获得药物临床试验批准

智通财经
Jul 08, 2025

智通财经APP讯,恒瑞医药(600276.SH)发布公告,近日,公司子公司广东恒瑞医药有限公司收到国家药品监督管理局(“国家药监局”)核准签发关于HRS-9821吸入粉雾剂的《药物临床试验批准通知书》,将于近期开展临床试验。

据悉,HRS-9821是小分子PDE3/PDE4 抑制剂,可有效抑制呼吸道炎症、扩张支气管,临床拟用于COPD的维持治疗。目前全球同类产品仅Ensifentrine于2024 年7月在美国获批上市,用于COPD的维持治疗。经查询EvaluatePharma数据库,2024年Ensifentrine全年销售额约为4,200万美元。截至目前,HRS-9821相关项目累计研发投入约3,843万元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10